Hillstream Biopharma (CNTN) and The Competition Head-To-Head Review

Hillstream Biopharma (NASDAQ:CNTN) is one of 226 public companies in the “Pharmaceutical Preparations” industry, but how does it weigh in compared to its competitors? We will compare Hillstream Biopharma to similar businesses based on the strength of its profitability, earnings, dividends, risk, institutional ownership, valuation and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Hillstream Biopharma and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1	0	0	0	1.00
Hillstream Biopharma Competitors	2231	2463	4375	69	2.25

As a group, “Pharmaceutical Preparations” companies have a potential upside of 120.16%. Given Hillstream Biopharma’s competitors stronger consensus rating and higher possible upside, analysts clearly believe Hillstream Biopharma has less favorable growth aspects than its competitors.

Profitability

This table compares Hillstream Biopharma and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-35.59%	-27.05%
Hillstream Biopharma Competitors	-4,803.12%	-250.26%	-48.16%

Volatility & Risk

Hillstream Biopharma has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500. Comparatively, Hillstream Biopharma’s competitors have a beta of 12.16, indicating that their average stock price is 1,116% more volatile than the S&P 500.

Valuation & Earnings

This table compares Hillstream Biopharma and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Hillstream Biopharma	N/A	-$35.92 million	-0.82
Hillstream Biopharma Competitors	$333.00 million	-$26.96 million	-4.51

Hillstream Biopharma’s competitors have higher revenue and earnings than Hillstream Biopharma. Hillstream Biopharma is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

1.2% of Hillstream Biopharma shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceutical Preparations” companies are held by institutional investors. 6.7% of Hillstream Biopharma shares are held by company insiders. Comparatively, 14.7% of shares of all “Pharmaceutical Preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Hillstream Biopharma competitors beat Hillstream Biopharma on 9 of the 13 factors compared.

About Hillstream Biopharma

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2019 and is based in Bridgewater, New Jersey.